Syndax Pharmaceuticals Inc
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
About Syndax Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for cancer and immunological conditions. Its approved therapies include revumenib, an oral menin inhibitor for patients with genetically defined acute leukemias, and axatilimab, a targeted antibody for patients with refractory chronic graft-versus-host disease. The company also evaluates these compounds across additional clinical indications, including myelofibrosis and idiopathic pulmonary fibrosis. Its end users are pediatric and adult patients receiving specialized hematology and oncology care.
Syndax is based in New York, New York, where it maintains its principal executive offices. The company commercializes its approved products and conducts clinical development programs within the United States, operating directly and in partnership with collaborative biopharmaceutical organizations and cooperative research networks.
Summary of the business section of Syndax Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Syndax Pharmaceuticals Inc
- Headquarters
- New York, NY
- Address
- 730 Third Avenue, 9th Floor 10017
- Phone
- (781) 419-1400
- Employees
- 298, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, New York, New York
Stock & identifiers
- Ticker
- SNDX
- Exchange
- Nasdaq
- IPO date
- Mar 3, 2016
- Shares outstanding
- 89M, Jul 31, 2026
- Public float
- $799.20M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1395937
- CUSIP
- 87164F105
- ISIN
- US87164F1057
- LEI
- 529900OF94TRHKZVBS87
- EIN
- 32-0162505
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael A. Metzger | Chief Executive Officer, Director | 517,218 |
| Nicholas A.J. Botwood | Head of R&D, CMO | 60,885 |
| Keith A. Goldan | Chief Financial Officer | 139,252 |
| Neil Gallagher | President, Head of R&D | 85,095 |
| Aleksandra Rizo | Director | 49,000 |
| Martin H. Huber Jr. | Director | 103,000 |
| Dennis Podlesak | Director | 239,763 |
| Pierre Legault | Director | 114,000 |
| Keith Katkin | Director | 124,000 |
| Jennifer Jarrett | Director | 114,000 |
| William Meury | Director | 90,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Briggs WMorrison | $0 | $0 | $2.45M | $94 | $125 |
| FY2025 Michael AMetzger | $7.09M | $11.13M | $2.45M | $94 | $125 |
| FY2024 Briggs WMorrison | $0 | $0 | $2.62M | $59 | $93 |
| FY2024 Michael AMetzger | $7.71M | $1.64M | $2.62M | $59 | $93 |
| FY2023 Briggs WMorrison | $0 | $0 | $3.03M | $97 | $94 |
| FY2023 Michael AMetzger | $9.13M | $5.21M | $3.03M | $97 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 298 full-time employees of which 144 were primarily engaged in research and development activities and 65 with M.D., Ph.D., or PharmD degree.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 3, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 2, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |